
PharmaMar Group announces financial results for fiscal year 2024
PharmaMar Group’s total revenue as of December 31st, 2024, grew by 11% over 2023 to €174.9 million. Royalties from sales increased by 18% to €61.3 million. Revenue from license agreements rose by 38% to €46.5 million. R&D investment amounted to €103.5 …